JPH0219319A - ラクツロースシロップから単離したフラクション及びこれを有効成分とする抗内毒素作用を有する医薬組成物 - Google Patents
ラクツロースシロップから単離したフラクション及びこれを有効成分とする抗内毒素作用を有する医薬組成物Info
- Publication number
- JPH0219319A JPH0219319A JP1127974A JP12797489A JPH0219319A JP H0219319 A JPH0219319 A JP H0219319A JP 1127974 A JP1127974 A JP 1127974A JP 12797489 A JP12797489 A JP 12797489A JP H0219319 A JPH0219319 A JP H0219319A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- endotoxin
- lactulose
- lactulose syrup
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 title claims abstract description 14
- 229960000511 lactulose Drugs 0.000 title claims abstract description 14
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 230000001986 anti-endotoxic effect Effects 0.000 title claims abstract description 10
- 239000006188 syrup Substances 0.000 title claims abstract description 9
- 235000020357 syrup Nutrition 0.000 title claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 230000009471 action Effects 0.000 title description 3
- 239000011347 resin Substances 0.000 claims abstract description 6
- 229920005989 resin Polymers 0.000 claims abstract description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 6
- 150000001768 cations Chemical class 0.000 claims abstract description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims abstract description 5
- 238000006317 isomerization reaction Methods 0.000 claims abstract description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 208000037487 Endotoxemia Diseases 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000002158 endotoxin Substances 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000003390 tumor necrosis factor Human genes 0.000 description 9
- 239000000203 mixture Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8801349 | 1988-05-26 | ||
| NL8801349 | 1988-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0219319A true JPH0219319A (ja) | 1990-01-23 |
Family
ID=19852354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1127974A Pending JPH0219319A (ja) | 1988-05-26 | 1989-05-23 | ラクツロースシロップから単離したフラクション及びこれを有効成分とする抗内毒素作用を有する医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5128323A (OSRAM) |
| EP (1) | EP0345850B1 (OSRAM) |
| JP (1) | JPH0219319A (OSRAM) |
| AT (1) | ATE81590T1 (OSRAM) |
| AU (1) | AU612843B2 (OSRAM) |
| DE (1) | DE68903246T2 (OSRAM) |
| DK (1) | DK249789A (OSRAM) |
| ES (1) | ES2033076T3 (OSRAM) |
| GR (1) | GR3006759T3 (OSRAM) |
| IL (1) | IL90388A (OSRAM) |
| NZ (1) | NZ229247A (OSRAM) |
| ZA (1) | ZA893944B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034064A (en) * | 1988-09-01 | 1991-07-23 | Snow Brand Milk Products Co., Ltd. | Production process of high-purity lactulose syrup |
| AU660325B2 (en) * | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
| RU2113466C1 (ru) * | 1997-02-28 | 1998-06-20 | Николай Яковлевич Дыкало | Способ обработки алкогольных напитков |
| US6270755B1 (en) | 1999-05-13 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders |
| US6290946B1 (en) * | 1999-05-13 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders and antibacterial agents |
| CA2314494A1 (en) | 2000-05-02 | 2001-11-02 | Geltex Pharmaceuticals, Inc. | Anionic polymers as species specific antibacterial agents |
| EP1542706A1 (en) * | 2002-07-22 | 2005-06-22 | Genzyme Corporation | Poly (potassium and sodium styrene sulfonate), its manufacture and its uses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2524414A (en) * | 1946-06-26 | 1950-10-03 | Univ Ohio State Res Found | Chromatographic separation of carbohydrates |
| JPS522984B1 (OSRAM) * | 1971-05-22 | 1977-01-25 | ||
| GB1501700A (en) * | 1975-10-02 | 1978-02-22 | Portals Water Treatment Ltd | Lactose hydrolysis using ion exchange resins |
| US4536221A (en) * | 1982-12-17 | 1985-08-20 | Sirac Spa | Process for preparing lactulose from lactose, in the form of a syrup or a crystalline product |
| IT1163540B (it) * | 1983-06-20 | 1987-04-08 | Sirac Srl | Procedimento per la purificazione dello sciroppo di lattulosio |
| IT1206140B (it) * | 1984-03-22 | 1989-04-14 | Sirac Srl | Procedimento per la purificazione di lattulosio. |
| IT1235866B (it) * | 1987-12-01 | 1992-11-23 | Sirac Srl | Processo per la preparazione di lattolosio da lattosio mediante epimerizzazione con alluminato sodico |
| IT1223398B (it) * | 1987-12-01 | 1990-09-19 | Sirac Spa | Procedimento per la preparazione di lattulosio cristallino ad alta purezza |
| IT1224438B (it) * | 1987-12-30 | 1990-10-04 | Sirac Srl | Processo per l'ottenimento di sciroppi di lattulosio ad elevata purezza e sciroppo cosi' ottenuto |
| DK72989A (da) * | 1988-02-22 | 1989-08-23 | Duphar Int Res | Fremgangsmaade til fremstilling af en fast komposition af lactulose |
-
1989
- 1989-05-23 DK DK249789A patent/DK249789A/da not_active Application Discontinuation
- 1989-05-23 JP JP1127974A patent/JPH0219319A/ja active Pending
- 1989-05-23 US US07/355,505 patent/US5128323A/en not_active Expired - Fee Related
- 1989-05-23 IL IL90388A patent/IL90388A/xx unknown
- 1989-05-24 EP EP89201329A patent/EP0345850B1/en not_active Expired - Lifetime
- 1989-05-24 ES ES198989201329T patent/ES2033076T3/es not_active Expired - Lifetime
- 1989-05-24 AT AT89201329T patent/ATE81590T1/de active
- 1989-05-24 DE DE8989201329T patent/DE68903246T2/de not_active Expired - Fee Related
- 1989-05-24 AU AU35157/89A patent/AU612843B2/en not_active Ceased
- 1989-05-24 ZA ZA893944A patent/ZA893944B/xx unknown
- 1989-05-26 NZ NZ229247A patent/NZ229247A/en unknown
-
1993
- 1993-01-11 GR GR930400015T patent/GR3006759T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU612843B2 (en) | 1991-07-18 |
| IL90388A0 (en) | 1989-12-15 |
| GR3006759T3 (OSRAM) | 1993-06-30 |
| DE68903246T2 (de) | 1993-03-11 |
| EP0345850B1 (en) | 1992-10-21 |
| EP0345850A1 (en) | 1989-12-13 |
| ES2033076T3 (es) | 1993-03-01 |
| DK249789A (da) | 1989-11-27 |
| DK249789D0 (da) | 1989-05-23 |
| NZ229247A (en) | 1991-06-25 |
| IL90388A (en) | 1993-08-18 |
| ZA893944B (en) | 1990-02-28 |
| US5128323A (en) | 1992-07-07 |
| AU3515789A (en) | 1989-11-30 |
| DE68903246D1 (de) | 1992-11-26 |
| ATE81590T1 (de) | 1992-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Danner et al. | Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X. | |
| Chaturvedi et al. | Survival of human milk oligosaccharides in the intestine of infants | |
| US4602003A (en) | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia | |
| JPS60224697A (ja) | チゴゲニンセロビオシドおよび医薬 | |
| ATE77053T1 (de) | Verfahren zur herstellung zuckerinkrustierter methylcellulosepartikel zur verwendung in abfuehrmitteln. | |
| Davidson et al. | Structural Studies on Chondroitin Sulfuric Acid. II. The Glucuronidic Linkage1, 2 | |
| McIntyre et al. | Effect of three nonsteroidal anti-inflammatory agents on platelet function and prostaglandin synthesis in vitro | |
| EP0345850B1 (en) | Composition having anti-endotoxic activity | |
| US5041427A (en) | Lipid A derivatives | |
| GB1213445A (en) | Plate for thin layer chromatography | |
| Matsuura et al. | Interferon‐inducing, pyrogenic and proclotting enzyme of horseshoe crab activation activities of chemically synthesized lipid A analogues | |
| Feldman et al. | Comparative effects of tetracyclines on water flow across toad urinary bladders | |
| FI67559C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbar 3-0-(beta-d-glukuronopyranosyl)-soijasapogenol b | |
| Neiderhiser et al. | The purification and properties of the glycoproteins of pig gallbladder bile | |
| Iwase et al. | Aggregated human serum immunoglobulin A1 induced by neuraminidase treatment had a lower number of O-linked sugar chains on the hinge portion | |
| Shaban et al. | The synthesis of O-α-D-mannopyranosyl-(1→ 6)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→ 4)-2-acetamido-2-deoxy-D-glucose | |
| US4371524A (en) | Anticomplementary agents comprising soyasapogenol B compounds | |
| Tsukamoto et al. | Metabolism of Drugs. XXXV. Metabolic Fate of Meprobamate.(3). A New Metabolic Pathway of Carbamate Group: The Formation of Meprobamate N-Glucuronide in Animal Body. | |
| Endo | Induction of hypoglycaemia and accumulation of 5-hydroxytryptamine in the liver after the injection of mitogenic substances into mice | |
| Wolfrom et al. | Degradation of glycogen to isomaltose | |
| Carstensen et al. | Nature of bonding in montmorillonite adsorbates I: surface adsorption | |
| Inamo et al. | Host responses and neuroendocrinological changes in pyrexia in childhood | |
| AU679970B2 (en) | Novel disaccharide derivative | |
| Inokuchi et al. | Immunochemical characterization of mouse brain-associated theta (Thy-1) antigen | |
| McFarland et al. | Sodium and Potassium Binding by Microsomes from Nasal Salt Gland, Harder's Gland, Kidney and Liver of Sea Gull. |